Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Biological studies of amiclenomycin

T Kitahara, K Hotta, M Yoshida

The Journal of Antibiotics

|March 1, 1975

Summary

Amiclenomycin selectively inhibits mycobacterial growth by blocking a key step in biotin synthesis. This antibiotic

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.

ESMO open·2024

Same author

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.

ESMO open·2022

Same author

Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].

ESMO open·2022

Same author

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

ESMO open·2022

Same author

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.

ESMO open·2022

Same author

Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.

ESMO open·2021

Area of Science:

Microbiology
Biochemistry
Drug Discovery

Background:

Amiclenomycin (AM) exhibits in vitro specificity against mycobacteria but lacks in vivo efficacy.
Biotin biosynthesis involves several enzymatic steps, crucial for microbial survival.

Purpose of the Study:

To elucidate the precise mechanism of action of amiclenomycin (AM) in microbial growth inhibition.
To investigate the interaction of AM with biotin biosynthesis pathways.

Main Methods:

In vitro antimicrobial susceptibility testing against various microorganisms.
Analysis of metabolite accumulation (7-keto-8-aminopelargonic acid [KAPA] and desthiobiotin [DTB]) in microbial cultures.
Investigating the reversal of AM's action by biotin precursors.

Main Results:

Amiclenomycin's inhibitory effect was reversed by biotin, desthiobiotin (DTB), and 7,8-diaminopelargonic acid (DAPA).
Accumulation of KAPA and decreased DTB formation were observed in Mycobacterium smegmatis and Bacillus sphaericus cultures treated with AM.
AM was found to inhibit the KAPA-DAPA transamination step in biotin biosynthesis.

Conclusions:

Amiclenomycin specifically targets and inhibits the KAPA-DAPA transamination step in the biotin biosynthesis pathway.
This inhibition explains AM's antimicrobial activity against certain bacteria.
The findings provide a basis for understanding synergistic antibiotic effects, such as with actithiazic acid.

Related Experiment Videos